Breakthrough in Oncology: Novel ADC Rolditamig Deuderuxtecan Triples Progression-Free Survival in HER2-Low Breast Cancer

MADRID — In a landmark development for the treatment of metastatic breast cancer, researchers have unveiled results from the phase III APEX-Breast01 trial, demonstrating that the novel antibody-drug conjugate (ADC)…

Novel Bispecific Antibody Tovecimig Shows Efficacy in Biliary Tract Cancer, Though Survival Benefit Remains Ambiguous

By Medical News Desk October 24, 2026 In a significant development for the treatment of aggressive gastrointestinal malignancies, results from the phase II/III COMPANION-002 clinical trial have offered a nuanced…